Development of a surface plasmon resonance immunosensor and ELISA for 3-nitrotyrosine in human urine.

Journal: Talanta
PMID:

Abstract

3-Nitrotyrosine (3-NT) is thought to be a relevant biomarker of nitrosative stress which is associated with many inflammatory and chronic diseases. It is necessary to develop confidential method for specific and sensitive 3-NT detection. In this paper, on the basis of anti-3-NT specific antibody, we developed a label-free indirect competitive surface plasmon resonance (SPR) immunosensor and ELISA for the detection of 3-NT. Under the optimized conditions, the SPR immunosensor can obtain a linear range of 0.17-6.07 μg/mL and a limit of detection (LOD) of 0.12 μg/mL while the ELISA can reach 0.33-9.94 μg/mL and a LOD of 0.24 μg/mL.The selectivity of 3-NT was also testified by six kinds of amino acid analogues. Besides, the developed SPR immunosensor was compared thoroughly with a conventional ELISA in spiked analysis of urine samples. Good recoveries and correlation between these two methods were observed (R = 0.964). Therefore, it is concluded that the automated SPR platform can be applied to quantify 3-NT in biological samples with its sensitivity, accuracy, and real-timing.

Authors

  • Qiyi He
    Department of Pharmaceutical Engineering, Faculty of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, People's Republic of China. Electronic address: chesto36@163.com.
  • Yingshan Chen
    Department of Pharmaceutical Engineering, Faculty of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, People's Republic of China. Electronic address: Chenysgdut@163.com.
  • Ding Shen
    Department of Pharmaceutical Engineering, Faculty of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, People's Republic of China. Electronic address: shending92@163.com.
  • Xiping Cui
    Department of Pharmaceutical Engineering, Faculty of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, People's Republic of China. Electronic address: cuixiping1989@163.com.
  • Chunguo Zhang
    Department of Pharmaceutical Engineering, Faculty of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, People's Republic of China. Electronic address: cgzhang1994@163.com.
  • Huiyi Yang
    Department of Pharmaceutical Engineering, Faculty of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, People's Republic of China. Electronic address: iyiuhgnay@163.com.
  • Wenying Zhong
    Department of Pharmaceutical Engineering, Faculty of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, People's Republic of China. Electronic address: wenying9602@163.com.
  • Sergei A Eremin
    Faculty of Chemistry, M. V. Lomonosov Moscow State University, 119991 Moscow, Russia; National Research Technical University MISiS, 119049 Moscow, Russia. Electronic address: eremin_sergei@hotmail.com.
  • Yanxiong Fang
    Department of Pharmaceutical Engineering, Faculty of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, People's Republic of China. Electronic address: fangyx@gdut.edu.cn.
  • Suqing Zhao
    Department of Pharmaceutical Engineering, Faculty of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, People's Republic of China. Electronic address: sqzhao@gdut.edu.cn.